ADC Therapeutics cuts 17% of workforce, expects $10M annual savings; pre-sBLA meeting in Aug 2026

ADC Therapeutics SA

Workforce reduction of ~17% globally, expected to generate ~$10M annualized cost savings.
One-time pre-tax charges of ~$3M for severance and termination costs, mostly in Q2 2026.
Pre-sBLA meeting with FDA in August 2026 for ZYNLONTA in r/r DLBCL; sBLA submission planned for Q4 2026.
LOTIS-7 trial data anticipated by end of 2026; cash runway at least into 2028.
Reorganization driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.